Hand, Foot and Mouth Disease, Herpangina, Other EV71-associated Diseases
Conditions
Keywords
efficacy, safety, inactivated vaccine (Vero Cell) against EV71, EV71-associated diseases
Brief summary
Since its discovery in 1969, enterovirus 71 (EV71) has been recognised as a frequent cause of epidemics of hand-foot-mouth disease (HFMD) associated with severe neurological sequelae in a small proportion of cases. There has been a significant increase in EV71 epidemic activity throughout the Asia-Pacific region since 1997. Recent HFMD epidemics in this region have heen associated with a severe from of brainstem encephalitis associated with pulmonary oedema and high case-fatality rates. The data from the phase 1 and 2 trials suggested that the inactivated EV71 vaccine had a clinically acceptable safety and good immunogenicity for healthy Chinese children and infants. According to the immunogenicity and safety results, the 320U with adjuvant with immunizing schedule of two doses (per 28 day) will be applied in phase 3 clinical trial.
Interventions
BIOLOGICALinactivated vaccine (Vero Cell) against EV71
inactivated vaccine (vero cell) against EV71, 320U /0.5ml, two doses, on day0, 28
BIOLOGICAL0/0.5ml placebo
0/0.5ml placebo, two doses, on day0, 28
Sponsors
Bejing Vigoo Biological Co., LTD
Jiangsu Province Centers for Disease Control and Prevention
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
6 Months to 35 Months
Healthy volunteers
No
Inclusion criteria
Only subjects fulfilling all of the following criteria will be eligible for the study: * Healthy children aged from 6 to 35 months old * General good health as established by medical history and physical examination * The subjects' guardians are able to understand and sign the informed consent * Had never received the vaccine against EV71 * The subjects' guardians allow to comply with the requirements of the protocol * Available for all visits scheduled in this study * Subjects with temperature \<=37.0°C on axillary setting
Exclusion criteria
Subjects will not be eligible for the study if any of the following criteria is met: * Subject who has a medical history of HFMD * Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine * Family history of seizures or progressive neurological disease * Family history of congenital or hereditary immunodeficiency * Severe malnutrition or hypogenesis * Major congenital defects or serious chronic illness, including perinatal brain damage * Autoimmune disease * Bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with IM injections or blood draws * Asplenia, functional asplenia, or splenic excision * History of asthma, angioneurotic edema, diabetes or malignant tumour * History of thyroidectomy, or thyroid disease in last 12 months * Any acute infections in last 7 days * Any prior administration of immunodepressant or corticosteroids in last 6 months * Any prior administration of blood products in last 3 months * Any prior administration of other research vaccines or medicines in last 1 month * Any prior administration of attenuated live vaccine in last 15 days * Any prior administration of subunit or inactivated vaccines in last 7 days * Under the anti-TB prevention or therapy * Subjects with temperature \>37.0°C on axillary setting * Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| the incidence density of the EV71-associated diseases in the vaccine group and placebo group. | begin at day 56 up to 14 months | compare the incidence density of the EV71-associated diseases between the vaccine group and placebo group in Chinese children aged 6-35 months. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| GMI of the vaccine group and placebo group | 28 days after the second vaccination | compare the geometric mean fold increase (GMFI) of the vaccine group and placebo group in healthy children aged 6-35 months. |
| the frequency of all the adverse events in vaccine group and placebo group. | up to 14 months | compare frequency of all the solicited events, unsolicited adverse events and serious adverse events between vaccine group and placebo group. |
| Seropositive rate of the vaccine group | 8 months after first vaccination | calculate the seropositive rate of the vaccine group in Chinese children aged 6-35 months at month 8 after first vaccination. |
| Seroconversion rate of the vaccine group | 8 months after first vaccination | calculate the seroconversion rate of the vaccine group in Chinese children aged 6-35 months at month 8 after first vaccination. |
| GMT of the vaccine group | 8 months after first vaccination | calculate the geometric mean titre (GMT) of the vaccine group in Chinese children aged 6-35 months at month 8 after first vaccination. |
| Seropositive rate of the vaccine group and placebo group | 28 days after the second vaccination | compare the seropositive rate of the vaccine group and placebo group in healthy children aged 6-35 months. |
| GMT of the vaccine group and placebo group | 28 days after the second vaccination | compare the geometric mean titre (GMT) of the vaccine group and placebo group in healthy children aged 6-35 months. |
| Seroconversion rate of the vaccine group and placebo group | 28 days after the second vaccination | compare the Seroconversion rate of the vaccine group and placebo group in healthy children aged 6-35 months. |
Countries
China
Outcome results
None listed